Janux Therapeutics, Inc. JANX
We take great care to ensure that the data presented and summarized in this overview for Janux Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JANX
View all-
Orbimed Advisors LLC San Diego, CA4.28MShares$177 Million3.62% of portfolio
-
Bvf Inc San Francisco, CA2.92MShares$121 Million3.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$115 Million0.2% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.35MShares$97.5 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.97MShares$81.5 Million0.04% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$70.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.36MShares$56.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY1MShares$41.5 Million0.6% of portfolio
-
Cormorant Asset Management, LP Boston, MA750KShares$31.1 Million1.63% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ542KShares$22.5 Million0.07% of portfolio
Latest Institutional Activity in JANX
Top Purchases
Top Sells
About JANX
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Transactions at JANX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Jay Lichter |
SELL
Open market or private sale
|
Indirect |
1,500,000
-17.15%
|
$81,000,000
$54.75 P/Share
|
|
Jun 03
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
822,721
-17.15%
|
$44,426,934
$54.75 P/Share
|
|
Jun 03
2024
|
Avalon Ventures Xi, L.P. |
SELL
Open market or private sale
|
Direct |
677,279
-17.15%
|
$36,573,066
$54.75 P/Share
|
|
Jun 03
2024
|
Tighe Reardon Acting Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
822,721
-17.15%
|
$44,426,934
$54.75 P/Share
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
577,478
-64.0%
|
-
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
44,544
+50.0%
|
-
|
|
Feb 29
2024
|
Avalon Ventures Xi, L.P. |
SELL
Other acquisition or disposition
|
Direct |
438,722
-10.0%
|
-
|
|
Feb 29
2024
|
Sheila Gujrathi |
BUY
Other acquisition or disposition
|
Direct |
2,986
+2.69%
|
-
|
|
Feb 29
2024
|
Vickie L Capps |
BUY
Other acquisition or disposition
|
Direct |
1,493
+2.23%
|
-
|
|
Nov 13
2023
|
Jay Lichter |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Nov 13
2023
|
Tighe Reardon Acting Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Nov 13
2023
|
Avalon Ventures Xi, L.P. |
BUY
Open market or private purchase
|
Indirect |
849,854
+50.0%
|
$4,249,270
$5.87 P/Share
|
|
Jul 19
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
495,008
+5.75%
|
$5,940,096
$12.46 P/Share
|
|
Dec 29
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
40,400
-1.59%
|
$808,000
$20.3 P/Share
|
|
Dec 29
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
40,400
-1.59%
|
$808,000
$20.3 P/Share
|
|
Dec 21
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
119,400
-4.51%
|
$2,268,600
$19.0 P/Share
|
|
Dec 21
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
119,400
-4.51%
|
$2,268,600
$19.0 P/Share
|
|
Dec 16
2021
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
393,300
-12.93%
|
$7,472,700
$19.07 P/Share
|
|
Dec 16
2021
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
393,300
-12.93%
|
$7,472,700
$19.07 P/Share
|
|
Jun 15
2021
|
Avalon Ventures Xi, L.P. |
BUY
Open market or private purchase
|
Indirect |
629,411
+12.32%
|
$10,699,987
$17.0 P/Share
|
Last 12 Months Summary
| Other acquisition or disposition | 49K shares |
|---|---|
| Open market or private purchase | 3.04M shares |
| Open market or private sale | 3.82M shares |
|---|---|
| Other acquisition or disposition | 1.02M shares |